Gordon Naylor
Interim CEO (from Feb 2026), CSL Limited
Gordon Naylor is an Australian biotechnology executive who was appointed interim Chief Executive Officer of CSL Limited, effective 11 February 2026, after Paul McKenzie retired. A long-time CSL veteran who began his career as an engineer, he previously served as the company's Chief Financial Officer and as founding President of its influenza vaccine business, Seqirus.
Fast facts
| Role | Interim CEO (from Feb 2026) |
|---|---|
| Company | CSL Limited ASX:CSL |
| Sector | Healthcare / Biotechnology |
| Headquarters | VIC |
| In role since | 2026 |
| Education | Bachelor of Engineering (Honours); Graduate Diploma in Computer Science; Master of Business Administration, Melbourne Business School; Certified Practising Accountant; Fellow of the Australian Academy of Technological Sciences and Engineering. |
Background
Long-time CSL executive; former CSL CFO and founding President of Seqirus (influenza vaccines); appointed interim CEO in February 2026 after Paul McKenzie retired.
Career timeline
- 1987Joined CSL, later helping design and build the Broadmeadows plasma facility as its first Chief Engineer
- 2013Served as Chief Financial Officer of CSL
- 2015Became President of Seqirus, leading a turnaround that positioned it as a global influenza vaccines leader
- 2025Rejoined CSL after an earlier departure in 2019
- 2026Appointed interim CEO of CSL, effective 11 February, after Paul McKenzie's retirement
Notable
- Leads CSL Limited, one of Australia's largest biotechnology companies, as interim CEO.
- Has a roughly 33-year history with CSL, spanning engineering, supply chain, IT, finance and vaccines.
- Founding President of Seqirus, CSL's global influenza vaccine business, which he led through a turnaround.
- Previously served as CSL's Chief Financial Officer.
- A non-executive director of Orica Limited and former chair of Medical Developments International.
Frequently asked questions
Who is the interim CEO of CSL?
Gordon Naylor was appointed interim CEO of CSL Limited, effective 11 February 2026, after Paul McKenzie retired.
What is Gordon Naylor's background at CSL?
He has about 33 years of history with CSL, including as Chief Financial Officer and as founding President of the Seqirus influenza vaccine business.
Whom did Gordon Naylor succeed as CSL CEO?
He stepped into the interim role after Paul McKenzie retired.
What other board roles does Gordon Naylor hold?
He is a non-executive director of Orica Limited and has chaired Medical Developments International.
Public profiles
Sources
- https://investors.csl.com/pdf/34e826de-672e-4027-b147-b647bb4aa602/Paul-McKenzie-retires-Gordon-Naylor-appointed-interim-CEO.pdf
- https://www.capitalbrief.com/briefing/csl-chief-executive-paul-mckenzie-to-depart-today-62002a18-9c6a-457f-8e11-ef73bfe0b53c/
- https://www.csl.com/we-are-csl/our-leadership/gordon-naylor
Last verified 2026-07-13. Professionally-public, sourced information only.